Want to see GANX full AI Analyst Report?
GANX Stock Chart & Stats
$2.13
-$0.01(-0.44%)
At close: 4:00 PM EST
$2.13
-$0.01(-0.44%)
Day’s Range― - ―
52-Week Range$1.41 - $4.34
Previous CloseN/A
Volume74.47K
Average Volume (3M)1.11M
Market Cap
$69.53M
Enterprise Value$66.06
Total Cash (Recent Filing)$16.54M
Total Debt (Recent Filing)$672.30K
Price to Earnings (P/E)―
Beta2.15
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding42,654,037
10 Day Avg. Volume796,281
30 Day Avg. Volume1,109,132
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)5.72
Price to Sales (P/S)0.00
P/FCF Ratio-5.75
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.20Price Target Upside238.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.56
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Clearance / Phase 2 StartIND clearance is a structural de-risking event: it authorizes U.S. clinical development and lets the company activate multicenter Phase 2 enrollment across the U.S., Australia and Europe. This advances the program toward pivotal efficacy data and increases partnership and licensing optionality over the next 2–6 months.
Favorable Clinical Biomarker And Safety DataDurable biomarker engagement with strong safety and participant retention signals mechanism-of-action validity and tolerability. Such translational evidence materially raises the probability that later-stage trials can show clinical benefit, strengthening the scientific case for partnerships and longer-term program value.
Near-term Funding RunwayA runway into Q2 2027 gives management time to complete the Phase 1b extension and initiate Phase 2 without immediate financing. That structural cushion reduces near-term dilution risk, allows milestone-driven program execution, and increases flexibility to time capital raises after clinical catalysts.
Bears Say
Pre-revenue StatusBeing pre-revenue means long lead times to commercial cash flow and heavy dependence on successful clinical outcomes. With no product sales, the company must fund R&D from cash or financing, making its business model sensitive to trial setbacks and market conditions over the medium term.
Sustained Cash BurnMaterial negative operating and free cash flow indicate ongoing cash consumption that closely tracks accounting losses. Persistent burn creates structural pressure to raise capital before runway expiry, increasing the odds of dilution and diverting management focus to financing rather than pure R&D execution.
Equity Base Erosion / Funding DependenceFalling equity reflects cumulative losses and possible dilution, reducing balance-sheet resilience. A shrinking equity cushion heightens vulnerability to adverse clinical or operational shocks and makes future fundraising more dilutive or costly, constraining strategic optionality over the medium term.
Gain Therapeutics News
GANX FAQ
What was Gain Therapeutics, Inc.’s price range in the past 12 months?
Gain Therapeutics, Inc. lowest stock price was $1.41 and its highest was $4.34 in the past 12 months.
What is Gain Therapeutics, Inc.’s market cap?
Gain Therapeutics, Inc.’s market cap is $69.53M.
When is Gain Therapeutics, Inc.’s upcoming earnings report date?
Gain Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 15 days.
How were Gain Therapeutics, Inc.’s earnings last quarter?
Gain Therapeutics, Inc. released its earnings results on May 11, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.138 by $0.008.
Is Gain Therapeutics, Inc. overvalued?
According to Wall Street analysts Gain Therapeutics, Inc.’s price is currently Undervalued.
Does Gain Therapeutics, Inc. pay dividends?
Gain Therapeutics, Inc. does not currently pay dividends.
What is Gain Therapeutics, Inc.’s EPS estimate?
Gain Therapeutics, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Gain Therapeutics, Inc. have?
Gain Therapeutics, Inc. has 42,654,037 shares outstanding.
What happened to Gain Therapeutics, Inc.’s price movement after its last earnings report?
Gain Therapeutics, Inc. reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.138. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Gain Therapeutics, Inc.?
Currently, no hedge funds are holding shares in GANX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gain Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.20 (238.03% Upside)
$7.20 (238.03% Upside)
Blogger Sentiment
Bullish
GANX Sentiment 70%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
61.20%
Trailing 12-Months
Company Description
Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
GANX Stock 12 Month Forecast
Average Price Target
$7.20
▲(238.03% Upside)
Technical Analysis
Plus Therapeutics
―
ABVC BioPharma
―
PMV Pharmaceuticals
―
Prelude Therapeutics
―
Immix Biopharma
―
Ownership Overview
2.29%
Insiders
1.76% Mutual Funds
0.17% Other Institutional Investors
94.32% Public Companies and
Individual Investors